To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple Sclerosis
NCT ID: NCT01079975
Last Updated: 2014-07-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
301 participants
OBSERVATIONAL
2008-08-31
2012-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Depression and Immune Function in Multiple Sclerosis (MS)
NCT02740296
Determining Changes in Brain Structure Associated With Symptoms of Late-life Depression
NCT00178087
Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant Trial
NCT01887639
Neuroinflammation, Affective and Cognitive Symptoms in Major Depression and Psoriasis
NCT04423471
Combined Interventions for Treating Depression and Chronic Back Pain
NCT00158275
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OBJECTIVES
Primary objective:
* Identification of the predictive factors for the development of depression symptoms in subjects with MS in Argentina
Secondary objective:
* Evaluation of the proportion of subjects that develop depression symptoms during the follow up
The subjects will be managed with the clinical and therapeutic elements that the treating doctors considered appropriate, without modifying their decisions due to the subjects' inclusion into the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects with established MS diagnosis according to the revised Mc Donald criteria - 2005 in any of its clinical forms
* Subjects with signed informed consent
* Subjects wiling to follow the study procedure
Exclusion Criteria
* Subjects receiving antidepressant drugs at the moment of the initial evaluation
* Subjects with moderate or severe cognitive impairment
* Antecedents of any other psychiatric disease
* Subjects that were receiving or have received any experimental treatment during the 6 months before the inclusion
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck KGaA, Darmstadt, Germany
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roberto Rey, Neurologist
Role: PRINCIPAL_INVESTIGATOR
Instituto de Investigacion Neurológica (Uruguay 840), Capital Federal City, Buenos Aires , 1015 , Argentina
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto de Investigacion Neurológica (Uruguay 840)
Capital Federal, Buenos Aires, Argentina
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EMR 200077- 500
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.